Anbar T S, Westerhof W, Abdel-Rahman A T, El-Khayyat M A
Department of Dermatology, Al-Minya University, Al-Minya, Egypt.
Photodermatol Photoimmunol Photomed. 2006 Jun;22(3):157-63. doi: 10.1111/j.1600-0781.2006.00222.x.
Narrow band (NB)-UVB has been used in the treatment of vitiligo for years but statistical evaluation of the clinical response in both segmental and non-segmental vitiligo patients has yet to be assessed.
Statistical evaluation of the clinical response of vitiligo patients to NB-UVB in both segmental and non-segmental types affecting different body sites.
This study included 150 patients with vitiligo either segmental (10%) or non-segmental (90%). NB-UVB therapy was given twice weekly till reaching our end point of 100% re-pigmentation or a cut point in unresponsive cases. Evaluation of the percentage of re-pigmentation was performed by total body photography and planimetry every 8 weeks.
The overall response to therapy in the non-segmental vitiligo group demonstrated that 48% of the patients showed marked response, 27% showed moderate response and 25% showed mild response after UVB therapy. The patients showed marked response in 76.3% in face lesions, 41.9% in trunk lesions and 37.6% in limbs lesions. None of the patients in the acral areas achieved marked response. The mean duration of therapy was 7.8 months. Moreover, the results demonstrated that the earlier the patient was treated, the better the response was especially for lesions on the face, trunk and limbs. On the other hand, in the segmental vitiligo group, patients showed no more than mild response to NB-UVB whatever the site of the lesion was. No side effects were encountered with NB-UVB therapy except for aggravation of the disease in two cases and erythema in one patient who was an outdoor worker and was skin type II.
The type of vitiligo, the affected anatomical area and the disease duration are important factors that influence potential re-pigmentation.
窄谱（NB）-UVB多年来一直用于白癜风的治疗，但尚未对节段型和非节段型白癜风患者的临床反应进行统计学评估。
对影响不同身体部位的节段型和非节段型白癜风患者对NB-UVB的临床反应进行统计学评估。
本研究纳入150例白癜风患者，其中节段型（10%），非节段型（90%）。NB-UVB治疗每周两次，直至达到100%复色的终点或确定无反应病例的截断点。每8周通过全身摄影和面积测量法评估复色百分比。
非节段型白癜风组的总体治疗反应显示，UVB治疗后48%的患者显示明显反应，27%显示中度反应，25%显示轻度反应。面部皮损患者76.3%显示明显反应，躯干皮损患者41.9%显示明显反应，四肢皮损患者37.6%显示明显反应。肢端部位的患者均未达到明显反应。平均治疗持续时间为7.8个月。此外，结果表明患者治疗越早，反应越好，尤其是面部、躯干和四肢皮损。另一方面，在节段型白癜风组中，无论皮损部位如何，患者对NB-UVB的反应均不超过轻度。NB-UVB治疗未出现副作用，仅两例病情加重，一例户外工作且皮肤类型为II型的患者出现红斑。
白癜风类型、受累解剖区域和病程是影响潜在复色的重要因素。
